17th Expert Committee: Applications for:
Additional formulations:
Additional medicines:
- Amantadine and rimantadine (Inclusion)
- Amiodarone (Inclusion)
- Antiemetic medicines (Inclusion) -- Paediatrics [NEW]
- Antipsychotic and antidepressive medicines (Inclusion)
- Antituberculosis medicines (Inclusion) -- Paediatrics [NEW]
- Artemether + lumefantrine (Inclusion) -- Paediatrics
- Atazanavir (Inclusion) -- [NEW]
- Captopril (Inclusion) -- Paediatrics
- Carboplatin (Inclusion)
- Carvedilol (Inclusion) -- Paediatrics
- Endar (Inclusion)
- Escitalopram oxalate (Inclusion)
- Hydroxycarbamide (Inclusion)
- Ibuprofen (Inclusion) -- Paediatrics
- Ifosfamide (Inclusion)
- Lamotrigine (Inclusion)
- Liposomal amphotericin B (Inclusion) -- Paediatrics [NEW]
- Lorazepam (Inclusion)
- Mesna (Inclusion)
- Midazolam (Inclusion)
- Misoprostol (Inclusion)
- Nicotine Replacement Therapy (NRT) (Inclusion)
- Nifurtimox + eflornithine (Inclusion)
- Omeprazole (Inclusion)
- Oral rehydration salts (Inclusion) [NEW]
- Oseltamivir (Inclusion)
- Paroxetine hydrochloride (Inclusion)
- Pralidoxime (Inclusion)
- Rifabutin (Inclusion)
- Sertraline hydrochloride (Inclusion)
- Sumatriptan (Inclusion)
- Tranexamic acid (Inclusion)
- Zanamivir (Inclusion)
- Zidovudine + lamivudine + abacavir (Inclusion) -- [NEW]
Re-instatement:
Possible deletion:
Review:
Contact: emlsecretariat@who.int
Medicine Access and Rational Use (MAR)
20 Avenue Appia
CH-1211 Geneva 27